Omega Diagnostics Group PLC Result of General Meeting and Total Voting Rights (8714N)
June 06 2022 - 9:29AM
UK Regulatory
TIDMODX
RNS Number : 8714N
Omega Diagnostics Group PLC
06 June 2022
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulation (EU) No. 596/2014. Upon the publication
of this announcement via the Regulatory Information Service, this
inside information is now considered to be in the public
domain.
OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
Result of General Meeting
And
Total Voting Rights
Omega (AIM: ODX), the specialist medical diagnostics company
focused on industry-leading Health & Nutrition and Global
Health products, announces, further to the announcement of 6 May
2022, the passing of the Resolution at the General Meeting held
earlier today. The Subscription and Open Offer remain conditional
on Admission of the New Ordinary Shares to AIM which is expected to
take place at 8.00 a.m. Wednesday 8 June 2022.
Voting details
The vote for the Resolution was carried out as a poll on the
basis of proxies received and the votes of those present
(11,815,745 for and 1,179,038 against, with 82,576 votes withheld),
and on the basis of such poll it was resolved that the Resolution
as contained in the Notice be passed as a Special Resolution.
Total Voting Rights
With effect from Admission the Company will have 237,685,180
Ordinary Shares in issue, with no shares held in treasury.
Shareholders may use this figure as the denominator by which they
are required to notify their interest in, or change to their
interest in, the Company under the Disclosure Guidance and
Transparency Rules.
Capitalised terms not otherwise defined in the text of this
announcement have the meanings given to them in the Company's
circular dated 13 May 2022.
Contacts:
Omega Diagnostics Group PLC www.omegadx.com
Jag Grewal, Chief Executive Officer via Walbrook PR
Chris Lea, Chief Financial Officer
finnCap Ltd Tel: 020 7220 0500
Geoff Nash/Edward Whiley/George Dollemore (Corporate
Finance)
Alice Lane/ Harriet Ward (ECM)
Walbrook PR Limited Tel: 020 7933 8780 or omega@walbrookpr.com
Paul McManus Mob: 07980 541 893
Lianne Applegarth Mob: 07584 391 303
Sam Allen Mob: 07502 558 258
About Omega Diagnostics Group PLC
Omega manufactures and distributes high quality in-vitro
diagnostic products for use in hospitals, clinics, laboratories and
healthcare practitioners in over 70 countries and specialise in the
areas of health and nutrition and global health.
www.omegadx.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVREADKKEADAEFA
(END) Dow Jones Newswires
June 06, 2022 09:29 ET (13:29 GMT)
Omega Diagnostics (LSE:ODX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Omega Diagnostics (LSE:ODX)
Historical Stock Chart
From Sep 2023 to Sep 2024